Developmental disorders Cell Models for Research

Developmental disorders encompass a broad range of conditions including intellectual disability, autism spectrum disorder (ASD), and attention deficit/hyperactivity disorder (ADHD). According to the World Health Organization (WHO), approximately 1 in 6 children globally experience some form of developmental disability. The prevalence of ASD is estimated at 1 in 100 children worldwide, with significant variation across regions. Intellectual disability affects about 1-3% of the population. These conditions often persist into adulthood, leading to lifelong challenges in daily functioning and social integration. The economic burden is substantial, with costs related to healthcare, education, and lost productivity. Early diagnosis and intervention are critical, but many underlying molecular mechanisms remain poorly understood, highlighting the need for robust research models.

Developmental disorders are ideal for mechanistic studies due to their genetic heterogeneity and the availability of well-characterized patient cohorts. Many genes implicated in these disorders are involved in synaptic function, neuronal development, and chromatin remodeling. Public datasets such as the Simons Simplex Collection (SSC) and the Autism Sequencing Consortium provide extensive genetic data. However, functional validation of candidate genes is often lacking. Gene-edited cell models, particularly isogenic lines derived from induced pluripotent stem cells (iPSCs) or immortalized neuronal lines, offer a controlled system to study the impact of specific mutations. These models enable researchers to dissect pathogenic mechanisms, screen for therapeutic compounds, and explore gene-environment interactions. The ability to generate isogenic pairs differing only in the target mutation is invaluable for establishing causality.

Several key pathways are frequently disrupted in developmental disorders:

• • Synaptic signaling: Genes encoding postsynaptic density proteins (e.g., SHANK, DLGAP) and neurotransmitter receptors (e.g., GRIN, GABRB) are often mutated. Disruption leads to altered synaptic transmission and plasticity.
• • Transcriptional regulation: Mutations in chromatin remodelers (e.g., CHD8, ARID1B) and transcription factors (e.g., FOXP1, TBR1) affect gene expression programs critical for neuronal differentiation.
• • mTOR signaling: Overactivation of the PI3K-AKT-mTOR pathway, as seen in TSC1/TSC2 mutations, leads to abnormal cell growth and synaptic dysfunction.
• • Wnt signaling: Aberrant Wnt signaling, often due to mutations in CTNNB1 or APC, disrupts neural progenitor proliferation and differentiation.

Data from ClinVar, NCBI Gene, and COSMIC (for somatic mutations in cancer, but germline variants are cataloged in ClinVar).

Key signaling networks implicated in developmental disorders:

• • PI3K-AKT-mTOR: Mutations in PTEN, TSC1/2, and AKT lead to hyperactivation, affecting cell growth and synaptic function.
• • Ras-MAPK: Mutations in HRAS, KRAS, and NF1 cause RASopathies, leading to cognitive deficits and cardiac abnormalities.
• • Wnt/β-catenin: Disruption of CTNNB1 or APC alters neural stem cell maintenance and differentiation.
• • Notch signaling: Mutations in NOTCH1 or DLL1 impair neurogenesis and are linked to Alagille syndrome.
• • Synaptic scaffolding: SHANK family mutations disrupt postsynaptic density assembly, affecting glutamatergic signaling.

Organoids recapitulate early brain development and are particularly useful for studying neurodevelopmental disorders. They allow for the investigation of cell-type-specific effects and cell-cell interactions in a 3D context.

Animal models are essential for studying developmental disorders in a whole-organism context.

• • Genetically engineered mouse models (GEMMs): Knockout or knock-in mice for genes like MECP2, FMR1, and SHANK3 recapitulate key phenotypes.
• • Induced models: Chemical or viral-induced models, e.g., valproic acid exposure in mice to model ASD.
• • Patient-derived xenograft (PDX) models: Less common for developmental disorders, but used for brain tumors that co-occur with these conditions.
• • Non-human primate models: CRISPR-edited monkeys for genes like MECP2 are being developed, but ethical and practical considerations limit their use.

CRISPR-based gene editing has revolutionized the generation of isogenic cell models for developmental disorders. By introducing precise mutations into a control cell line, researchers can create isogenic pairs that differ only in the target gene, enabling direct functional comparisons. For example:

• • A CHD8 knockout in SH-SY5Y cells can be used to study the effects on chromatin remodeling and gene expression.
• • A SCN2A knock-in carrying a patient-specific missense mutation can be used to assess neuronal excitability.
• • Isogenic iPSC-derived neurons with a TSC2 knockout can be differentiated to study mTOR pathway dysregulation.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing validated models that are ready to use. These models are generated using CRISPR-Cas9 technology and are rigorously quality-controlled, ensuring reproducibility. They are essential for drug discovery, functional genomics, and target validation.

Gene-edited cell models are invaluable for functional genomics, allowing researchers to:

• • Validate the role of candidate genes identified in patient cohorts.
• • Perform high-throughput loss-of-function screens using CRISPR libraries.
• • Study gene-gene interactions by generating double knockouts.

For example, a SYNGAP1 knockout in neurons can be used to investigate synaptic plasticity deficits and identify downstream effectors.

Isogenic cell lines are ideal for drug screening:

• • Phenotypic screens: Identify compounds that rescue disease-relevant phenotypes, such as reduced synaptic activity.
• • Target-based screens: Validate drug candidates that modulate the activity of the mutated protein.
• • Resistance studies: In cancer, but also relevant for developmental disorders, where drug resistance may emerge in long-term treatments.

For example, a TSC2 knockout cell line can be used to screen for mTOR inhibitors that normalize cell growth.

CRISPR-engineered cells can be used to discover biomarkers:

• • Synthetic lethality screens: Identify genes that, when silenced, are lethal only in the context of a specific mutation. This can reveal novel therapeutic targets.
• • Secretome analysis: Compare the secretome of mutant vs. wild-type cells to identify potential biomarkers for early diagnosis.
• • Transcriptomic profiling: Identify differentially expressed genes that could serve as biomarkers or therapeutic targets.